At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 3, 2026 at 06:00 ET
Esperion Therapeutics is acquiring Corstatis Therapeutics to gain full rights to Enbumyst™, the first FDA-approved nasal spray diuretic for edema associated with congestive heart failure, liver, and kidney disease. The deal includes a $75 million upfront cash payment, up to $180 million in potential milestone payments, and low double-digit royalties on future sales, with financing from existing credit facilities and royalty monetization. The acquisition expands Esperion’s cardiovascular portfolio and leverages its commercial infrastructure to target a U.S. market opportunity exceeding $4 billion.
- Esperion is acquiring Corstasis Therapeutics to add Enbumyst™ (bumetanide nasal spray) to its portfolio.
- Enbumyst is the first and only FDA-approved nasal spray loop diuretic, approved in September 2025 for edema in CHF, hepatic, and renal disease.
- Deal includes $75 million upfront cash payment, up to $180 million in milestone payments, and low double-digit royalties on global sales.
- Transaction expected to close in Q2 2026, financed through existing credit facilities and royalty monetization with Athyrium and HealthCare Royalty.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access